专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

CZ3848U1 Protection medium for protecting rabies virus 未知
公开(公告)号：CZ3848U1
公开(公告)日：1995-11-15
申请号：CZ421895
申请日：1995-07-19
申请人： OPAVET , DEDEK LADISLAV , KRECMEROVA KRISTINA , MATOUCH OLDRICH MVDR CSC
发明人： DEDEK LADISLAV MVDR CSC , KRECMEROVA KRISTINA , MATOUCH OLDRICH MVDR CSC
IPC分类号： A61K39/205 , A61K039/205

2. 发明申请

US20010031267A1 Method for treatment of canine distemper 失效
标题翻译：犬瘟热症治疗方法
公开(公告)号：US20010031267A1
公开(公告)日：2001-10-18
申请号：US09747551
申请日：2000-12-22
发明人： John McMichael
IPC分类号： A61K039/205 , A01N037/18 , A61K038/00 , A61K039/155
CPC分类号： A61K39/175 , A61K39/12 , A61K2039/5254 , A61K2039/552 , A61K2039/70 , C12N2760/18434 , Y10S424/818
摘要： The present invention relates to a treatment for animals having canine distemper by administering a composition comprising an attenuated canine distemper virus a sub-vaccine virus level effective to alleviate symptoms canine distemper. The invention also provides a treatment for animals having canine distemper by administering a composition comprising an attenuated canine measles virus a sub-vaccine virus level effective to alleviate symptoms canine distemper.
摘要翻译：本发明涉及通过施用包含减毒犬瘟热病毒的组合物来治疗具有犬瘟热的动物，该组合物有效减轻犬瘟热症状的亚疫苗病毒水平。本发明还提供了对具有犬瘟热的动物的治疗，其通过施用包含减毒的麻疹病毒的组合物，其有效减轻犬瘟热症状的亚疫苗病毒水平。

3. 发明申请

US20030124146A1 Recombinant Rhabdoviruses as live-viral vaccines 审中-公开
标题翻译：重组弹状病毒作为活病毒疫苗
公开(公告)号：US20030124146A1
公开(公告)日：2003-07-03
申请号：US10150165
申请日：2002-05-16
发明人： Matthias J. Schnell , Roger J. Pomerantz
IPC分类号： A61K039/205 , C07H021/04 , C12N007/00 , C12N015/86
CPC分类号： C12N15/86 , A61K2039/525 , A61K2039/5256 , A61K2039/545 , A61K2039/57 , C07K14/005 , C07K2319/00 , C12N7/00 , C12N2710/24143 , C12N2710/24164 , C12N2740/15022 , C12N2740/16122 , C12N2760/20022 , C12N2760/20043 , C12N2770/24222
摘要： This invention provides recombinant, replication-competent Rhabdovirus vaccine strain-based expression vectors for expressing heterologous viral antigenic polypeptides such as immunodeficiency virus envelope proteins or subparts thereof. An additional transcription stop/start unit within the Rhabdovirus genome is inserted to express the heterologous antigenic polypeptides. The HIV-1 gp160 protein is stably and functionally expressed, as indicated by fusion of human T cell-lines after infection with the recombinant RVs. Inoculation of mice with the recombinant Rabies viruses expressing HIV-1 gp160 induces a strong humoral response directed against the HIV-1 envelope protein after a single boost with an isolated recombinant HIV-1 gp120 protein. Moreover, high neutralization titers, up to 1:800, against HIV-1 are detected in the mouse sera. These recombinant viral vectors expressing viral antigenic polypeptides provide useful and effective pharmaceutical compositions for the generation of viral-specific immune responses.
摘要翻译：本发明提供用于表达异源病毒抗原性多肽（例如免疫缺陷病毒包膜蛋白或其子部分）的重组，基于复制能力的基于弹状病毒基因毒株的表达载体。插入Rhabdovirus基因组内的另外的转录停止/起始单位以表达异源抗原多肽。 HIV-1 gp160蛋白质是稳定和功能表达的，如通过重组RV感染后的人T细胞系的融合所表明的。用重组的表达HIV-1 gp160的狂犬病病毒接种小鼠，用分离的重组HIV-1 gp120蛋白单次加强后，诱导针对HIV-1包膜蛋白的强烈体液应答。此外，在小鼠血清中检测到针对HIV-1的高达1：800的高中和滴度。这些表达病毒抗原多肽的重组病毒载体提供了用于产生病毒特异性免疫应答的有用和有效的药物组合物。

4. 发明申请

US20030099671A1 Attenuated rabies virus with nucleoprotein mutation at the phosphorylation site for vaccination against rabies and gene therapy in the CNS 失效
公开(公告)号：US20030099671A1
公开(公告)日：2003-05-29
申请号：US10199024
申请日：2002-07-22
发明人： Zhen Fang Fu
IPC分类号： C12Q001/68 , A61K048/00 , A01N063/00 , A61K039/12 , A61K039/205 , C12N007/00 , C12N007/01 , C12N005/00 , C12N005/02
CPC分类号： C12N7/00 , A61K39/12 , A61K39/205 , A61K48/00 , A61K2039/5254 , C07K14/005 , C12N15/86 , C12N2760/20122 , C12N2760/20134 , C12N2760/20143 , C12N2760/20161
摘要： A mutant virus is provided which contains a mutation at a phosphorylation site in one or more of the proteins of the virus, which mutation causes the virus to be attenuated, and therefore, an improved vaccine composition can be produced therewith. The invention also relates to vaccine compositions which contain the mutant virus, as well as to methods of inducing an immune response, and of protecting mammals from infection by rabies virus. Also included in the invention are methods of producing the mutant virus and mutant viral proteins, including producing the mutant virus in a host cell which produces or even overproduces a wild-type counterpart of the mutant viral protein, which complements the other viral proteins such that production of the mutant viral particle is optimized. The invention also includes those host cells in which viral production is optimized, as well as vaccine compositions including the viral proteins, either alone or in combination with the intact virus, and to methods of inducing an immune response or protecting a mammal from infection, using the same. Also included in the invention are vectors suitable for delivering a gene to a cell of a human or animal, as well methods of delivery thereof.

5. 发明申请

US20030091590A1 Recombinant rhabdoviruses as live-viral vaccines 审中-公开
标题翻译：重组弹状病毒作为活病毒疫苗
公开(公告)号：US20030091590A1
公开(公告)日：2003-05-15
申请号：US10127746
申请日：2002-04-19
发明人： Roger J. Pomerantz , Matthias J. Schnell
IPC分类号： C12P021/06 , C12P019/34 , A61K039/12 , A61K039/205 , C12N015/00 , C12N015/09 , C12N015/63 , C12N015/70 , C12N015/74
CPC分类号： C12N15/86 , A61K2039/525 , A61K2039/545 , A61K2039/57 , C07K14/005 , C07K2319/00 , C12N7/00 , C12N2710/24143 , C12N2710/24164 , C12N2740/15022 , C12N2740/16122 , C12N2760/20122 , C12N2760/20143 , C12N2770/24222
摘要： This invention provides recombinant, replication-competent Rhabdovirus vaccine strain-based expression vectors for expressing heterologous viral antigenic polypeptides such as immunodeficiency virus envelope proteins or subparts thereof. An additional transcription stop/start unit within the Rhabdovirus genome is inserted to express the heterologous antigenic polypeptides. The HIV-1 gp160 protein is stably and functionally expressed, as indicated by fusion of human T cell-lines after infection with the recombinant RVs. Inoculation of mice with the recombinant Rabies viruses expressing HIV-1 gp160 induces a strong humoral response directed against the HIV-1 envelope protein after a single boost with an isolated recombinant HIV-1 gp120 protein. Moreover, high neutralization titers, up to 1:800, against HIV-1 are detected in the mouse sera. These recombinant viral vectors expressing viral antigenic polypeptides provide useful and effective pharmaceutical compositions for the generation of viral-specific immune responses.
摘要翻译：本发明提供用于表达异源病毒抗原性多肽（例如免疫缺陷病毒包膜蛋白或其子部分）的重组，基于复制能力的基于弹状病毒基因毒株的表达载体。插入Rhabdovirus基因组内的另外的转录停止/起始单位以表达异源抗原多肽。 HIV-1 gp160蛋白质是稳定和功能表达的，如通过重组RV感染后的人T细胞系的融合所表明的。用重组的表达HIV-1 gp160的狂犬病病毒接种小鼠，用分离的重组HIV-1 gp120蛋白单次加强后，诱导针对HIV-1包膜蛋白的强烈体液应答。此外，在小鼠血清中检测到针对HIV-1的高达1：800的高中和滴度。这些表达病毒抗原多肽的重组病毒载体提供了用于产生病毒特异性免疫应答的有用和有效的药物组合物。

6. 发明申请

US20040208900A1 Attenuated rabies virus with nucleoprotein mutation at the phosphorylation site for vaccination against rabies and gene therapy in the CNS 失效
标题翻译：在CNS的狂犬病疫苗接种和基因治疗的磷酸化位点具有核蛋白突变的减毒狂犬病毒
公开(公告)号：US20040208900A1
公开(公告)日：2004-10-21
申请号：US10730029
申请日：2003-12-09
申请人： University of Georgia Research Foundation, Inc.
发明人： Zhen Fang Fu
IPC分类号： A61K039/205
CPC分类号： C12N7/00 , A61K39/12 , A61K39/205 , A61K48/00 , A61K2039/5254 , C07K14/005 , C12N15/86 , C12N2760/20122 , C12N2760/20134 , C12N2760/20143 , C12N2760/20161
摘要： A mutant virus is provided which contains a mutation at a phosphorylation site in one or more of the proteins of the virus, which mutation causes the virus to be attenuated, and therefore, an improved vaccine composition can be produced therewith. The invention also relates to vaccine compositions which contain the mutant virus, as well as to methods of inducing an immune response, and of protecting mammals from infection by rabies virus. Also included in the invention are methods of producing the mutant virus and mutant viral proteins, including producing the mutant virus in a host cell which produces or even overproduces a wild-type counterpart of the mutant viral protein, which complements the other viral proteins such that production of the mutant viral particle is optimized. The invention also includes those host cells in which viral production is optimized, as well as vaccine compositions including the viral proteins, either alone or in combination with the intact virus, and to methods of inducing an immune response or protecting a mammal from infection, using the same. Also included in the invention are vectors suitable for delivering a gene to a cell of a human or animal, as well methods of delivery thereof.
摘要翻译：提供了突变病毒，其在病毒的一种或多种蛋白质中的磷酸化位点处含有突变，该突变导致病毒减毒，因此可以用其产生改进的疫苗组合物。本发明还涉及含有突变病毒的疫苗组合物，以及诱导免疫应答的方法，以及保护哺乳动物不被狂犬病病毒感染。本发明还包括产生突变病毒和突变病毒蛋白质的方法，包括在宿主细胞中产生突变病毒，所述宿主细胞产生甚至过度产生突变病毒蛋白质的野生型对应物，其补充其他病毒蛋白质，使得优化突变病毒颗粒的生产。本发明还包括其中优化病毒生产的那些宿主细胞以及包含病毒蛋白的疫苗组合物，其单独或与完整病毒组合，以及诱导免疫应答或保护哺乳动物感染的方法，使用一样。本发明还包括适合将基因递送至人或动物的细胞的载体，以及其递送方法。

7. 发明申请

US20030017172A1 Feline polynucleotide vaccine formula 有权
公开(公告)号：US20030017172A1
公开(公告)日：2003-01-23
申请号：US09943443
申请日：2001-08-30
发明人： Jean-Christophe Audonnet , Annabelle Bouchardon , Philippe Baudu , Michel Riviere
IPC分类号： A61K048/00 , A61K039/295 , A61K039/205 , C12N015/86
CPC分类号： C07K14/005 , A61K2039/51 , C12N2710/16722 , C12N2710/16734 , C12N2740/13022 , C12N2740/13034 , C12N2740/15022 , C12N2740/15034 , C12N2750/14322 , C12N2750/14334 , C12N2760/20022 , C12N2760/20122 , C12N2760/20134 , C12N2760/20222 , C12N2760/20234 , C12N2770/16034 , C12N2770/20022 , C12N2770/20034
摘要： Disclosed are plasmids that contain and express in vivo in a feline host cell nucleic acid molecules. The plasmid can include nucleic molecule(s) having sequence(s) encoding infectious peritonitis virus M; feline immunodeficiency virus env, or gag, or pro, or gag and pro, or env and gag and pro; rabies G; or feline leukemia virus env and/or gag. Compositions containing such plasmids, methods of use employing such plasmids, and kits involving such plasmids, are also disclosed.

8. 发明申请

US20020155436A1 Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae 失效
公开(公告)号：US20020155436A1
公开(公告)日：2002-10-24
申请号：US10124363
申请日：2002-04-18
发明人： John Barthelow Classen
IPC分类号： C12Q001/70 , A61K039/00 , A61K039/38 , A61K039/295 , A61K039/205 , A61K039/10
CPC分类号： A61K39/07 , A61K39/0017 , A61K39/0018 , A61K39/0208 , A61K39/05 , A61K39/08 , A61K39/099 , A61K2039/58 , A61K2039/70 , Y02A50/386 , Y02A50/388 , Y02A50/39 , Y02A50/401 , Y02A50/407 , Y02A50/41 , Y02A50/412 , Y02A50/423 , Y02A50/466 , Y02A50/484
摘要： A method of immunization, and compositions therefor, are provided for substantially preventing or reducing the symptoms of at least one infectious disease and at least one chronic immune mediated disorder. An immunogenic challenge which supplements the normal childhood immunization schedule can help ensure the proper maturation of the immune system and prevent the development of chronic immune mediated disorders, such as immune-mediated diabetes or SLE.

9. 发明申请

US20040109879A1 Method of Treating Herpes Virus Infections 审中-公开
标题翻译：治疗疱疹病毒感染的方法
公开(公告)号：US20040109879A1
公开(公告)日：2004-06-10
申请号：US10604591
申请日：2003-08-01
申请人： UNIVERSITY OF SOUTH FLORIDA
发明人： Thomas B. Freeman , G. Michael Nauert
IPC分类号： A61K039/205
CPC分类号： A61K39/205 , A61K39/12 , A61K2039/5252 , A61K2039/58 , C12N2760/20134
摘要： The present invention is a novel alternative use of the rabies vaccine for the purposes of suppressing herpes outbreaks.
摘要翻译：本发明是用于抑制疱疹爆发的狂犬病疫苗的新型替代用途。

10. 发明申请

US20040096462A1 Noval vaccine formulation consisting of dna vaccine and inactivated virus 审中-公开
标题翻译： Noval疫苗制剂由dna疫苗和灭活病毒组成
公开(公告)号：US20040096462A1
公开(公告)日：2004-05-20
申请号：US10451854
申请日：2003-06-23
发明人： Pundi Narasimhan Rangarajan , Villuppanoor Alwar Srinivasan , Subhabrata Biswas , Guddeti Sreenivasa Reddy
IPC分类号： A61K039/12 , A61K039/205
CPC分类号： C07K14/005 , A61K2039/53 , A61K2039/55505 , C12N2760/20122
摘要： Disclosed herein is a novel vaccine formulation for prophylatic or therapeutic immunization of vertebrates against infections caused by vertebrate viruses. The said vaccine contains a minimum of two components, one of which is a deoxyribonucleotide (DNA) vaccine comprising of a DNA molecule that encodes a polypeptide of the virus and the other component consisting of inactivated form of the virus. This invention can also be used to develop low cost inactivated virus-based vaccines that contain much lower amount of the said virus than that present in similar vaccines known in the prior art. This invention also relates to a process of producing that said novel vaccine formulation and the use of the said formulation.
摘要翻译：本文公开了一种用于针对脊椎动物病毒引起的感染的脊椎动物的预防或治疗性免疫的新型疫苗制剂。所述疫苗含有至少两种组分，其中之一是脱氧核糖核酸（DNA）疫苗，其包含编码病毒多肽的DNA分子和由灭活形式的病毒组成的其它组分。本发明还可用于开发与现有技术中已知的类似疫苗中存在的病毒相比低得多的基于病毒的低成本疫苗。本发明还涉及生产所述新型疫苗制剂和所述制剂的用途的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式